Randomized, double-blind, Phase 1 trial of an alphavirus replicon vaccine for cytomegalovirus in CMV seronegative adult volunteers
- 1 December 2009
- Vol. 28 (2) , 484-493
- https://doi.org/10.1016/j.vaccine.2009.09.135
Abstract
No abstract availableKeywords
Funding Information
- AlphaVax, Inc.
This publication has 34 references indexed in Scilit:
- Vaccine Prevention of Maternal Cytomegalovirus InfectionNew England Journal of Medicine, 2009
- Therapeutic and prophylactic applications of alphavirus vectorsExpert Reviews in Molecular Medicine, 2008
- Safety and Immunogenicity of a Bivalent Cytomegalovirus DNA Vaccine in Healthy Adult SubjectsThe Journal of Infectious Diseases, 2008
- Development and preclinical evaluation of an alphavirus replicon particle vaccine for cytomegalovirusVaccine, 2007
- Development and preclinical evaluation of an alphavirus replicon vaccine for influenzaVaccine, 2007
- A Novel Alphavirus Vaccine Encoding Prostate-Specific Membrane Antigen Elicits Potent Cellular and Humoral Immune ResponsesClinical Cancer Research, 2007
- Comparison of Two Cancer Vaccines Targeting Tyrosinase: Plasmid DNA and Recombinant Alphavirus Replicon ParticlesClinical Cancer Research, 2005
- Broadly targeted human cytomegalovirus-specific CD4+ and CD8+ T cells dominate the memory compartments of exposed subjectsThe Journal of Experimental Medicine, 2005
- Cytotoxic T Lymphocyte (CTL) Responses to Human Cytomegalovirus pp65, IE1‐Exon4, gB, pp150, and pp28 in Healthy Individuals: Reevaluation of Prevalence of IE1‐Specific CTLsThe Journal of Infectious Diseases, 2000
- Use of Cytomegalovirus Immune Globulin to Prevent Cytomegalovirus Disease in Renal-Transplant RecipientsNew England Journal of Medicine, 1987